SB202190 (FHPI)
貨號(hào):C152121
規(guī)格:50mg
品牌:OrganRegen
產(chǎn)品介紹
DESCRIPTION
| |||
M. W t | 331.34 | ||
Formula | C20H14FN3O | ||
CAS No | |||
Storage | Powder | - 20°C | 3 years |
4°C | 2 year C20H14FN3O | ||
In solvent | -80°C | 6 months | |
-20°C | 1 month | ||
Solubility | DMSO | 100 mg/mL(301.80 mM; Need ultrasonic) | |
Ethanol | 12 mg/mL(36.22 mM) | ||
H2O | < 0.1 mg/mL(insoluble) |
技術(shù)參數(shù)
BIOLOGICAL ALTIVITY
In Vitro
SB202190 (0-10 μM; 0-72 hours) attenuates growth of a subgroup of CRC cell lines such as RKO, CACO2 and SW480 in a dose- and time-dependent manner[1].
SB 202190 strongly inhibited colony formation and anchorage-independent growth (10 μM for 7–10 days) and elevated apoptotic cell death (10 μM for 72 h) in this same subset of CRC lines (RKO, CACO2 and SW480)[2].
In RKO, CACO2 and SW480 cells, SB202190 (10 μM; 2 hours) abrogates phosphorylation of S6K1(T389) and S6(S235/236), but not AKT(S473), indicating that p38i selectively blocks mTORC1 signaling[2].
In Vivo
SB202190 (5 mg/kg; intraperitoneal injection; daily for 10-12 days) shows inhibition of tumor cell survival and tumor growth[2] .
REFERENCES